tiprankstipranks
Trending News
More News >
Perimeter Medical Imaging AI (TSE:PINK)
:PINK
Advertisement

Perimeter Medical Imaging AI (PINK) AI Stock Analysis

Compare
22 Followers

Top Page

TSE:PINK

Perimeter Medical Imaging AI

(PINK)

Select Model
Select Model
Select Model
Neutral 46 (OpenAI - 4o)
Rating:46Neutral
Price Target:
C$0.00
▼(-100.00% Downside)
The overall score reflects significant financial challenges, including profitability and cash flow issues, which are the most impactful factors. While the earnings call showed positive revenue growth and operational improvements, the ongoing net loss and limited cash reserves are critical concerns. Technical indicators and valuation metrics provide a mixed outlook, with no immediate signs of strong momentum or value.

Perimeter Medical Imaging AI (PINK) vs. iShares MSCI Canada ETF (EWC)

Perimeter Medical Imaging AI Business Overview & Revenue Model

Company DescriptionPerimeter Medical Imaging AI, Inc., a medical technology company, develops and commercializes advanced imaging tools that allow surgeons, radiologists, and pathologists to visualize microscopic tissue structures during a clinical procedure. The company offers an optical coherence tomography (OCT) imaging system provides clinicians with cross-sectional of tissues down to 2 mm dept. This OCT imaging system consists of S-series OCT, B-series OCT, and OCT imaging console. It also offers ImgAssist, an artificial intelligence technology that enhances the efficiency of image review and be an additional powerful tool when combined with Perimeter OCT to aid physicians with real-time margin visualization and assessment to improve surgical outcomes for patients and reducing the likelihood of needing additional surgeries. In addition, the company offers proprietary image library and consumable specimen containers to hospitals and cancer surgery centers. Perimeter Medical Imaging AI, Inc. was founded in 2013 and is headquartered in Toronto, Canada.
How the Company Makes MoneyPerimeter Medical Imaging AI generates revenue primarily through the sales of its imaging systems and associated consumables to hospitals and surgical centers. The company also earns income from ongoing service agreements and maintenance contracts for its devices. Additionally, Perimeter may derive revenue through partnerships and collaborations with healthcare institutions and research organizations that are interested in utilizing its technology for clinical studies or integration into their surgical workflows. The adoption of its products and technology within the healthcare sector, alongside potential licensing agreements for its AI algorithms, further contributes to its financial growth.

Perimeter Medical Imaging AI Earnings Call Summary

Earnings Call Date:Aug 26, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Nov 12, 2025
Earnings Call Sentiment Neutral
The earnings call reflects significant positive developments, such as strong revenue growth, positive trial results, and increased product utilization. However, challenges remain with an increased net loss, limited cash reserves, and constraints due to a small commercial team. While the highlights are impressive, the lowlights present notable hurdles that need addressing.
Q2-2025 Updates
Positive Updates
Significant Revenue Growth
The company recorded revenue of $506,000 for Q2 2025, representing a 105% increase over Q2 2024. Additionally, revenue for the first six months of 2025 was 25% higher than the total for all of 2024.
Improved Operating Expenses
Operating expenses for Q2 2025 were $4.3 million, a 22% improvement from $5.5 million in the same period in 2024.
Positive Clinical Trial Results
The pivotal trial of Perimeter B-Series met its primary endpoint, demonstrating a statistically significant reduction in patients with residual cancer during surgery. The trial results were positively received at the ASBRS conference.
Increased Product Utilization
Utilization rates increased 93% year-over-year and 35% sequentially quarter-over-quarter. Surgeons have imaged over 3,000 patients using the company's technology.
Negative Updates
Net Loss Increase
Second quarter 2025 net loss was $3.9 million compared to $3.2 million in the same period in 2024.
Low Cash Reserves
As of June 30, 2025, cash and cash equivalents were approximately $1.4 million, not including recent financial inputs.
Limited Commercial Team
The company's ability to meet growing demand is limited by the size of its commercial team, affecting its capacity to accelerate sales.
Company Guidance
During the Perimeter Medical Second Quarter 2025 Conference Call, key financial and operational metrics were highlighted. The company recorded $506,000 in revenue for the quarter ending June 30, 2025, marking a 105% increase from Q2 2024. The gross margin remained consistent at 70%. Operating expenses decreased by 22% to $4.3 million compared to the same period in 2024. Despite these improvements, Perimeter reported a net loss of $3.9 million. The company had cash and cash equivalents of approximately $1.4 million, excluding $1.6 million from a recent offering and a $745,000 grant receivable. The CEO, Adrian Mendes, emphasized ongoing efforts to commercialize the FDA-cleared S-Series OCT system, with a 25% revenue increase in the first half of 2025 compared to all of 2024. Utilization rates showed significant growth of 93% year-over-year and 35% sequentially. The company is awaiting FDA approval for its next-generation B-Series device, expected by late Q4 2025 or Q1 2026, and is preparing for an aggressive rollout. Cost-saving measures are projected to reduce operating expenses by approximately 30% starting in Q3.

Perimeter Medical Imaging AI Financial Statement Overview

Summary
Perimeter Medical Imaging AI shows revenue growth but struggles with profitability and cash flow. The low debt-to-equity ratio is positive, but negative returns on equity and cash flow issues are significant concerns.
Income Statement
35
Negative
Perimeter Medical Imaging AI shows a positive revenue growth trend with a 19.99% increase in TTM, indicating potential market traction. However, the company is struggling with profitability, as evidenced by negative net profit margins and EBIT margins, reflecting ongoing operational challenges.
Balance Sheet
40
Negative
The company maintains a low debt-to-equity ratio of 0.026, suggesting conservative leverage. However, the negative return on equity indicates that the company is not generating profits from its equity base, which is a concern for long-term sustainability.
Cash Flow
30
Negative
The cash flow statement reveals negative operating and free cash flows, with a declining free cash flow growth rate. The operating cash flow to net income ratio is negative, highlighting cash flow challenges despite a positive free cash flow to net income ratio.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.56M846.19K403.53K132.77K11.34K0.00
Gross Profit968.18K535.11K206.42K100.63K5.04K-47.57K
EBITDA-15.46M-12.64M-17.92M-11.72M-15.95M-6.11M
Net Income-16.29M-13.39M-18.94M-3.59M-16.76M-8.00M
Balance Sheet
Total Assets6.92M14.33M27.09M34.60M9.98M13.16M
Cash, Cash Equivalents and Short-Term Investments1.37M6.18M18.43M28.44M5.14M11.70M
Total Debt117.05K137.48K192.89K325.68K441.17K400.81K
Total Liabilities2.41M3.87M7.10M8.49M2.56M2.40M
Stockholders Equity4.51M10.45M15.06M26.11M7.42M10.76M
Cash Flow
Free Cash Flow-15.78M-16.90M-15.17M-13.86M-16.03M-8.26M
Operating Cash Flow-13.86M-14.72M-14.70M-11.87M-13.91M-8.26M
Investing Cash Flow-1.80M-1.90M206.01K-1.75M-1.45M7.24M
Financing Cash Flow10.44M8.58M234.47K40.28M10.06M9.84M

Perimeter Medical Imaging AI Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price0.24
Price Trends
50DMA
0.24
Positive
100DMA
0.24
Negative
200DMA
0.35
Negative
Market Momentum
MACD
<0.01
Positive
RSI
50.45
Neutral
STOCH
24.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:PINK, the sentiment is Neutral. The current price of 0.24 is below the 20-day moving average (MA) of 0.24, above the 50-day MA of 0.24, and below the 200-day MA of 0.35, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 50.45 is Neutral, neither overbought nor oversold. The STOCH value of 24.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:PINK.

Perimeter Medical Imaging AI Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
C$250.94M-106.37%64.42%-21.09%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
49
Neutral
C$140.76M-9.69-9.96%-0.70%-102.48%
48
Neutral
C$23.42M-26.27%17.61%-19.19%
46
Neutral
C$29.10M-0.90-233.44%219.12%-15.92%
45
Neutral
C$53.98M-12.00-291.69%16.00%9.79%
44
Neutral
C$15.93M88.47%11.88%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:PINK
Perimeter Medical Imaging AI
0.24
-0.18
-42.86%
TSE:ASG
Aurora Spine
0.30
-0.14
-31.82%
TSE:QIPT
Quipt Home Medical
3.46
-0.29
-7.73%
TSE:PRN
Profound Medical
8.37
-3.61
-30.13%
TSE:TLT
Theralase Technologies
0.20
-0.09
-31.03%
TSE:VPT
VentriPoint Diagnostics
0.10
-0.04
-28.57%

Perimeter Medical Imaging AI Corporate Events

Business Operations and Strategy
Perimeter Medical Imaging AI Engages in Strategic Breast Surgery Forum
Positive
Oct 21, 2025

Perimeter Medical Imaging AI announced its participation in the American Society of Breast Surgeons’ Annual Strategic Futures Forum, a key event for healthcare leaders to discuss the future of breast surgery. This involvement allows Perimeter to engage with leaders in the breast surgeon community, potentially influencing their product development and enhancing breast care solutions. The forum’s theme emphasizes the importance of multi-disciplinary collaboration in improving breast care outcomes.

The most recent analyst rating on (TSE:PINK) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.

Business Operations and Strategy
Perimeter Medical Imaging AI to Present at Planet MicroCap Showcase
Positive
Oct 17, 2025

Perimeter Medical Imaging AI announced its participation in the Planet MicroCap Showcase in Toronto, where CEO Adrian Mendes will present updates on the company’s commercial strategy and upcoming milestones. This event, which gathers investors and analysts, provides Perimeter with an opportunity to enhance its industry positioning and engage with potential stakeholders, highlighting its focus on advanced imaging tools for cancer surgery.

The most recent analyst rating on (TSE:PINK) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.

Business Operations and Strategy
Perimeter Medical Imaging AI to Present at Virtual Investor Conference
Neutral
Oct 14, 2025

Perimeter Medical Imaging AI announced that its CEO, Adrian Mendes, will present an update on the company’s business at the Small Cap Growth Virtual Investor Conference. This presentation is significant as it targets a global audience of small-cap retail and institutional investors, potentially impacting the company’s visibility and investor relations. The company’s focus on advanced imaging tools for cancer surgery positions it strategically within the medical technology industry, with ongoing evaluations and developments that could influence its market presence.

The most recent analyst rating on (TSE:PINK) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.

Business Operations and StrategyProduct-Related Announcements
Perimeter Medical Imaging AI Showcases OCT Technology at Breast Cancer Summit
Positive
Sep 26, 2025

Perimeter Medical Imaging AI announced its participation in the Aptitude Health/TME’s Fall Summit on Breast Cancer Care, showcasing its innovative optical coherence tomography (OCT) technology. This event is a significant opportunity for Perimeter to present its technology to leading breast cancer physicians, potentially advancing intraoperative care and enhancing its market position in the medical imaging industry.

The most recent analyst rating on (TSE:PINK) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.

Business Operations and StrategyProduct-Related Announcements
Perimeter Medical Imaging AI Showcases Advanced Imaging at Clinical Assembly
Positive
Sep 19, 2025

Perimeter Medical Imaging AI announced that Dr. Amelia Tower will present at the American College of Osteopathic Surgeons’ Annual Clinical Assembly on the use of wide-field optical coherence tomography (OCT) in breast conserving surgery. The presentation will highlight the practical application of Perimeter’s S-Series OCT, which has FDA clearance, and its potential to reduce re-excision rates by providing real-time insights during surgery. This event underscores the growing clinical evidence supporting the integration of advanced imaging technologies in surgical workflows, potentially enhancing precision and decision-making in breast cancer surgeries.

The most recent analyst rating on (TSE:PINK) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.

Business Operations and StrategyExecutive/Board Changes
Perimeter Medical Imaging AI Partners with Breast Cancer Advocate Jennifer Douglas
Positive
Sep 16, 2025

Perimeter Medical Imaging AI has announced a collaboration with Jennifer Douglas, a breast cancer survivor and advocate, to enhance patient engagement initiatives. Douglas will join the company’s Industry Advisory Board, contributing her experience to support breast cancer patients and improve outcomes. This partnership is expected to strengthen Perimeter’s focus on patient support and expand its influence in the breast cancer community.

The most recent analyst rating on (TSE:PINK) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.

Business Operations and Strategy
Perimeter Medical Imaging AI Joins ASBrS Industry Relations Council
Positive
Sep 8, 2025

Perimeter Medical Imaging AI has joined the American Society of Breast Surgeons’ Industry Relations Council, a move that aligns with its strategic goals to enhance its presence in the breast surgery field. This membership is expected to facilitate collaboration with key industry leaders and support the company’s efforts to gain commercial traction for its current and next-generation imaging systems, potentially impacting its market positioning and stakeholder engagement.

The most recent analyst rating on (TSE:PINK) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.

Perimeter Medical Imaging AI: Earnings Call Insights
Sep 1, 2025

Perimeter Medical Imaging AI Inc. recently held its earnings call, revealing a mix of promising developments and ongoing challenges. The sentiment was largely positive, highlighted by strong revenue growth, successful clinical trials, and increased product utilization. However, the company faces hurdles such as rising net losses, limited cash reserves, and constraints from a small commercial team. These factors underscore the need for strategic adjustments moving forward.

Business Operations and StrategyExecutive/Board Changes
Perimeter Medical Imaging AI Appoints Dr. Ted James as Chief Medical Officer to Drive Growth
Positive
Aug 28, 2025

Perimeter Medical Imaging AI has appointed Dr. Ted James as Chief Medical Officer to bolster its medical strategy and accelerate the adoption of its technology. Dr. James, with extensive experience in surgical oncology and healthcare innovation, will support the company’s growth as it moves towards commercialization of its next-generation AI-enabled imaging tools. His appointment is expected to enhance the company’s industry positioning by demonstrating the medical and practical value of its Perimeter B-Series technology, which is advancing toward FDA approval.

The most recent analyst rating on (TSE:PINK) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.

Financial DisclosuresPrivate Placements and FinancingProduct-Related Announcements
Perimeter Medical Imaging AI Reports Strong Q2 2025 Results and Advances in Imaging Technology
Positive
Aug 26, 2025

Perimeter Medical Imaging AI reported a significant increase in revenue for the second quarter of 2025, driven by the growing adoption of its FDA-cleared Perimeter S-Series device. The company also highlighted the promising development of its next-generation Perimeter B-Series device, which integrates AI technology to improve surgical decision-making. Recent partnerships and the launch of a new registry aim to support further advancements in their imaging technology. The company’s financial health was bolstered by a successful prospectus offering, raising approximately $3.8 million to support ongoing operations and development efforts.

The most recent analyst rating on (TSE:PINK) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.

Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Perimeter Medical Imaging AI Reports Strong Q2 Growth and Strategic Leadership Changes
Positive
Aug 11, 2025

Perimeter Medical Imaging AI, Inc. announced preliminary unaudited revenues for the second quarter of 2025, showing significant growth with a 100% year-over-year increase and a 50% rise in recurring revenue compared to the previous quarter. The company is implementing a 30% reduction in operating costs and has made strategic leadership changes to support its growth, including the appointment of new vice presidents and the creation of an Industry Advisory Board to guide its commercial strategy.

The most recent analyst rating on (TSE:PINK) stock is a Buy with a C$3.00 price target. To see the full list of analyst forecasts on Perimeter Medical Imaging AI stock, see the TSE:PINK Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 31, 2025